Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.

Abstract

BACKGROUND:

Synergistic interactions between neprilysin inhibition (NEPi) with sacubitril and angiotensin receptor type1 blockade (ARB) with valsartan have been implicated in improvement of left ventricular (LV) contractility, relaxation, exercise tolerance, and fibrosis in preexisting heart failure (HF) induced by aortic valve insufficiency (AVI). It is not known whether this pharmacologic synergy can prevent cardiovascular pathology in a similar AVI model. Our aim was to investigate the pharmacology of sacubitril/valsartan in an experimental setting with therapy beginning immediately after creation of AVI.

METHODS:

HF was induced through partial disruption of the aortic valve in rats. Therapy began 3 hours after valve disruption and lasted 8 weeks. Sacubitril/valsartan (68 mg/kg), valsartan (31 mg/kg), sacubitril (31 mg/kg), or vehicle were administered daily via oral gavage (N=8 in each group). Hemodynamic assessments were conducted using Millar technology, and an exercise tolerance test was conducted using a rodent treadmill.

RESULTS:

Only sacubitril/valsartan increased total arterial compliance and ejection fraction (EF). Therapies with sacubitril/valsartan and valsartan similarly improved load-dependent (dP/dtmax) and load independent indices (Ees) of LV contractility, and exercise tolerance, whereas sacubitril did not. None of the therapies improved LV relaxation (dP/dtmin), whereas all reduced myocardial fibrosis.

CONCLUSIONS:

1) The synergistic interaction between NEPi and ARB in early therapy with sacubitril/valsartan leads to increased total arterial compliance and EF. 2) Improvement in indices of LV contractility, and exercise tolerance with sacubitril/valsartan is likely because of ARB effect of valsartan. 3) All three therapies provided antifibrotic effects, suggesting both ARB and NEPi are capable of reducing myocardial fibrosis.

• Authors: Mikhail Y Maslov, Stephan Foianini, Dita Mayer, Michael V Orlov, Mark A Lovich
• Journal: Journal of cardiac failure (J Card Fail) Vol. 25 Issue 11 Pg. 921-931 (Nov 2019) ISSN: 1532-8414 [Electronic] United States
• PMID: 31539619 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Aminobutyrates
• Angiotensin II Type 1 Receptor Blockers
• Angiotensin Receptor Antagonists
• Biphenyl Compounds
• Drug Combinations
• Tetrazoles
• Valsartan
• sacubitril and valsartan sodium hydrate drug combination

Topics

• Aminobutyrates (administration & dosage, metabolism)
• Angiotensin II Type 1 Receptor Blockers (administration & dosage, metabolism)
• Angiotensin Receptor Antagonists (administration & dosage, metabolism)
• Animals
• Aortic Valve Insufficiency (drug therapy, metabolism)
• Biphenyl Compounds
• Drug Combinations
• Drug Interactions (physiology)
• Drug Synergism
• Exercise Tolerance (drug effects, physiology)
• Heart Failure (drug therapy, metabolism)
• Male
• Rats
• Rats, Sprague-Dawley
• Stroke Volume (drug effects, physiology)
• Tetrazoles (administration & dosage, metabolism)
• Valsartan (administration & dosage, metabolism)